FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2754845467> ?p ?o ?g. }

• W2754845467 endingPage "11" @default.
• W2754845467 startingPage "4" @default.
• W2754845467 abstract "The purpose of our study was to assess 18F–DCFBC PET/CT, a PSMA targeted PET agent, for lesion detection and clinical management of biochemical relapse in prostate cancer patients after primary treatment. This is a prospective IRB-approved study of 68 patients with documented biochemical recurrence after primary local therapy consisting of radical prostatectomy (n = 50), post radiation therapy (n = 9) or both (n = 9), with negative conventional imaging. All 68 patients underwent whole-body 18F–DCFBC PET/CT, and 62 also underwent mpMRI within one month. Lesion detection with 18F–DCFBC was correlated with mpMRI findings and pre-scan PSA levels. The impact of 18F–DCFBC PET/CT on clinical management and treatment decisions was established after 6 months’ patient clinical follow-up. Forty-one patients (60.3%) showed at least one positive 18F–DCFBC lesion, for a total of 79 lesions, 30 in the prostate bed, 39 in lymph nodes, and ten in distant sites. Tumor recurrence was confirmed by either biopsy (13/41 pts), serial CT/MRI (8/41) or clinical follow-up (15/41); there was no confirmation in five patients, who continue to be observed. The 18F–DCFBC and mpMRI findings were concordant in 39 lesions (49.4%), and discordant in 40 lesions (50.6%); the majority (n = 32/40) of the latter occurring because the recurrence was located outside the mpMRI field of view. 18F–DCFBC PET positivity rates correlated with PSA values and 15%, 46%, 83%, and 77% were seen in patients with PSA values <0.5, 0.5 to <1.0, 1.0 to <2.0, and ≥2.0 ng/mL, respectively. The optimal cut-off PSA value to predict a positive 18F–DCFBC scan was 0.78 ng/mL (AUC = 0.764). A change in clinical management occurred in 51.2% (21/41) of patients with a positive 18F–DCFBC result, generally characterized by starting a new treatment in 19 patients or changing the treatment plan in two patients. 18F–DCFBC detects recurrences in 60.3% of a population of patients with biochemical recurrence, but results are dependent on PSA levels. Above a threshold PSA value of 0.78 ng/mL, 18F–DCFBC was able to identify recurrence with high reliability. Positive 18F–DCFBC PET imaging led clinicians to change treatment strategy in 51.2% of patients." @default.
• W2754845467 created "2017-09-25" @default.
• W2754845467 creator A5007290763 @default.
• W2754845467 creator A5020187186 @default.
• W2754845467 creator A5022455023 @default.
• W2754845467 creator A5024598099 @default.
• W2754845467 creator A5026122849 @default.
• W2754845467 creator A5027334479 @default.
• W2754845467 creator A5037190456 @default.
• W2754845467 creator A5038850729 @default.
• W2754845467 creator A5045920664 @default.
• W2754845467 creator A5049105246 @default.
• W2754845467 creator A5049568817 @default.
• W2754845467 creator A5054197287 @default.
• W2754845467 creator A5058176319 @default.
• W2754845467 creator A5062971835 @default.
• W2754845467 creator A5063392701 @default.
• W2754845467 creator A5067251812 @default.
• W2754845467 creator A5068012456 @default.
• W2754845467 creator A5068476777 @default.
• W2754845467 creator A5069493174 @default.
• W2754845467 creator A5074516558 @default.
• W2754845467 creator A5075590318 @default.
• W2754845467 creator A5076213753 @default.
• W2754845467 creator A5082080836 @default.
• W2754845467 date "2017-09-11" @default.
• W2754845467 modified "2023-09-24" @default.
• W2754845467 title "Clinical impact of PSMA-based 18F–DCFBC PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy" @default.
• W2754845467 cites W1517749817 @default.
• W2754845467 cites W1903999661 @default.
• W2754845467 cites W1919117211 @default.
• W2754845467 cites W1988587438 @default.
• W2754845467 cites W1994463565 @default.
• W2754845467 cites W1998345392 @default.
• W2754845467 cites W2014999922 @default.
• W2754845467 cites W2042635688 @default.
• W2754845467 cites W2053554578 @default.
• W2754845467 cites W2054244152 @default.
• W2754845467 cites W2080006760 @default.
• W2754845467 cites W2080957338 @default.
• W2754845467 cites W2106187131 @default.
• W2754845467 cites W2128021809 @default.
• W2754845467 cites W2133571839 @default.
• W2754845467 cites W2161309377 @default.
• W2754845467 cites W2230026600 @default.
• W2754845467 cites W2328176404 @default.
• W2754845467 cites W2346035477 @default.
• W2754845467 cites W2561039633 @default.
• W2754845467 cites W2588873924 @default.
• W2754845467 cites W286096609 @default.
• W2754845467 cites W3023689102 @default.
• W2754845467 cites W4293409513 @default.
• W2754845467 doi "https://doi.org/10.1007/s00259-017-3818-x" @default.
• W2754845467 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7983162" @default.
• W2754845467 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28894899" @default.
• W2754845467 hasPublicationYear "2017" @default.
• W2754845467 type Work @default.
• W2754845467 sameAs 2754845467 @default.
• W2754845467 citedByCount "53" @default.
• W2754845467 countsByYear W27548454672017 @default.
• W2754845467 countsByYear W27548454672018 @default.
• W2754845467 countsByYear W27548454672019 @default.
• W2754845467 countsByYear W27548454672020 @default.
• W2754845467 countsByYear W27548454672021 @default.
• W2754845467 countsByYear W27548454672022 @default.
• W2754845467 countsByYear W27548454672023 @default.
• W2754845467 crossrefType "journal-article" @default.
• W2754845467 hasAuthorship W2754845467A5007290763 @default.
• W2754845467 hasAuthorship W2754845467A5020187186 @default.
• W2754845467 hasAuthorship W2754845467A5022455023 @default.
• W2754845467 hasAuthorship W2754845467A5024598099 @default.
• W2754845467 hasAuthorship W2754845467A5026122849 @default.
• W2754845467 hasAuthorship W2754845467A5027334479 @default.
• W2754845467 hasAuthorship W2754845467A5037190456 @default.
• W2754845467 hasAuthorship W2754845467A5038850729 @default.
• W2754845467 hasAuthorship W2754845467A5045920664 @default.
• W2754845467 hasAuthorship W2754845467A5049105246 @default.
• W2754845467 hasAuthorship W2754845467A5049568817 @default.
• W2754845467 hasAuthorship W2754845467A5054197287 @default.
• W2754845467 hasAuthorship W2754845467A5058176319 @default.
• W2754845467 hasAuthorship W2754845467A5062971835 @default.
• W2754845467 hasAuthorship W2754845467A5063392701 @default.
• W2754845467 hasAuthorship W2754845467A5067251812 @default.
• W2754845467 hasAuthorship W2754845467A5068012456 @default.
• W2754845467 hasAuthorship W2754845467A5068476777 @default.
• W2754845467 hasAuthorship W2754845467A5069493174 @default.
• W2754845467 hasAuthorship W2754845467A5074516558 @default.
• W2754845467 hasAuthorship W2754845467A5075590318 @default.
• W2754845467 hasAuthorship W2754845467A5076213753 @default.
• W2754845467 hasAuthorship W2754845467A5082080836 @default.
• W2754845467 hasBestOaLocation W27548454672 @default.
• W2754845467 hasConcept C121608353 @default.
• W2754845467 hasConcept C126322002 @default.
• W2754845467 hasConcept C126838900 @default.
• W2754845467 hasConcept C143998085 @default.
• W2754845467 hasConcept C2775842073 @default.
• W2754845467 hasConcept C2776235491 @default.
• W2754845467 hasConcept C2779466945 @default.

• next